Brexit Health Alliance

Brexit could disrupt supply of medicines, Brexit Health Alliance warns

UK and EU flag

Patients could face disruption to the supply of their medicines when the UK leaves the EU,  according to the Brexit Health Alliance in a briefing paper published today, which is calling on both sides to put patients first.
The Alliance brings together the NHS, medical research, industry, patients and public health organisations to safeguard the interests of patients and the healthcare and research they rely on.

Brexit and the impact on patient access to medicines and medical technologies warns that unless a deal is reached medicines and medical technologies could  be delayed or even become unavailable to patients.
In an example, the Brexit Health Alliance is warning that up to 120,000 prostate cancer patients throughout Europe could be affected if Brexit negotiations fail to find a solution for future cooperation between the UK and the EU on regulation and trade of medicines and medical devices.
A prostate cancer medicine, made in a highly sophisticated process in the UK and used in 80 countries including all of Europe, is one of many medicines that risks supply disruption from a “no deal” scenario.
The future of research into new medicines and medical technologies could also be affected. Around 750 UK-led clinical trials including multiple EU member states could be at risk if there is no plan on how to approve and manage these multi-national trials with European partners after March 2019.
The aim of the Brexit Health Alliance is to secure a cooperation agreement between the UK and the EU on regulation of medicines and medical devices.

Niall Dickson, co-chair of the Brexit Health Alliance, said: “It is critical that UK and EU patients do not lose out on the best treatments and medical devices as the UK leaves the EU.

“We want to make sure that patients continue to benefit from early access to new health technologies and cutting-edge medicines, and that includes being able to take part in international clinical trials.

“This can be achieved if will is there – what patients need is maximum co-operation and alignment between the EU and the UK on the regulation of medicines and medical devices and we very much welcome the UK Government’s commitment to close collaboration with our European partners.

“Let’s put patients first - both the UK Government and European Commission must make this cooperation  priority in the interests of UK and EU patients.” 

Aisling Burnand, Chief Executive of the Association of Medical Research Charities, said: “It is vital that the health of patients is prioritised in the second phase of negotiations. If not, patients in the UK and the EU could face delays in accessing potentially life-saving treatments. Officials on both sides of the negotiating table must have patients’ best interests at heart and ensure safety considerations are paramount.”

Latest Tweets

Latest Blog Post

Tackling medicines wastage through a scalable initiative | Diar Fattah

14 / 12 / 2018 12.08pm

With estimates exceeding £300 million wasted every year in the NHS on unused or partially used medicine, Diar Fattah, associate director of medicines optimisation at Dartford, Gravesham and Swanley (DGS) CCG, believes savings and efficiency opportunities around medicines wastage are ripe for the taking.

Why Register?

Great reasons to register with NHS Confederation

  • Access exclusive resources 
    Access member-only resources and tailor member benefits and services
  • Personalise your website
    Select topics of interest for recommended content
  • Comment and recommend
    Rate and share content with colleagues
  • Never miss a thing
    Register now to keep your finger on the pulse of the NHS Confederation

Log In

To book events and access member only content you need to register with us.  This only takes a moment via our registration page. If you have already registered login using your email address and password below.